The U.S. Food and Drug Administration on Monday approved Alkermes Plc’s longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses.
Thank you for reading this post, don't forget to subscribe!Abilify, developed by Japanese drugmaker Otsuka Pharmaceuticals and sold in the United States by Bristol-Myers Squibb Co, is already facing generic competition.
Alkermes’ injectable version, Aristada, is expected to be launched immediately, the company said in a statement on Monday.